|
The FDA is warning
consumers to immediately stop use of the product Lipokinetix,
marketed as a dietary supplement (for weight loss) by Syntrax
Innovations, Inc. FDA has received multiple reports of persons who
developed liver injury or liver failure while using Lipokinetix. The
product contains norephedrine (also known as phenylpropanolamine or
PPA), caffeine, yohimbine, diiodothyronine, and sodium usniate. FDA
is also advising consumers to consult their physician if they are
experiencing symptoms possibly associated with this product,
particularly nausea, weakness or fatigue, fever, abdominal pain, or
any change in skin color.
More
Information on this story click here.
The MedWatch 2001
Safety Information summary for Lipokinetix is posted at:
http://www.fda.gov/medwatch/safety/2001/safety01.htm#lipoki
You can see the
FDA Center for Food Safety and Applied Nutrition (CFSAN) website
regarding dietary supplements at:
http://www.cfsan.fda.gov/~dms/supplmnt.html
MedWatch is your
Internet gateway for timely safety information on drugs and other
medical products regulated by the U.S. Food and Drug Administration.
Visit the MedWatch
web site regularly for the latest official safety information, at http://www.fda.gov/medwatch
Reprinted with
permission of MedWatch
Nurses
Referral Banner Exchange
This
site is a member of the Medical Banner Exchange
|
